Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European Union. Eur Urol 69:438–447
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108
Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F (2001) De novo muscle invasive bladder cancer: is there a change in trend? J Urol 165:47–50 (discussion 50)
Article CAS PubMed Google Scholar
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW et al (2013) Bladder cancer. J Natl Compr Cancer Netw JNCCN 11:446–475
Article CAS PubMed Google Scholar
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540-556.e25
Article CAS PubMed PubMed Central Google Scholar
Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT et al (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472:749–758
Article CAS PubMed PubMed Central Google Scholar
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165
Article CAS PubMed PubMed Central Google Scholar
Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544–554
Article CAS PubMed Google Scholar
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34
Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L (2010) Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 76:112–126
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75–94
Casey RG, Catto JWF, Cheng L, Cookson MS, Herr H, Shariat S et al (2015) Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol 67:876–888
Miyake M, Hirao S, Mibu H, Tanaka M, Takashima K, Shimada K et al (2011) Clinical significance of subepithelial growth patterns in non-muscle invasive bladder cancer. BMC Urol 11:17
Article PubMed PubMed Central Google Scholar
Kimura S, Mari A, Foerster B, Abufaraj M, Vartolomei MD, Stangl-Kremser J et al (2019) Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis. J Urol 201:46–53
Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42–48
Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E et al (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32:1295–1301
Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160
Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S et al (2021) Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling. Can Res 81:1552–1566
Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Tögel L et al (2021) TERT promoter mutation analysis of whole-organ mapping bladder cancers. Genes 12:230
Article CAS PubMed PubMed Central Google Scholar
Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM et al (2019) The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol Res 7:923–938
Article CAS PubMed Google Scholar
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C et al (2020) Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer 8:e000162
Article PubMed PubMed Central Google Scholar
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol 70:106–119
Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP et al (2021) The genitourinary pathology society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia. Adv Anat Pathol 28:179–195
R: the R project for statistical computing [Internet] [updated 2022 Apr 22; cited 2022 Jun 6]. Available from: https://www.r-project.org/.
Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Can Res 64:4040–4048
Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R (1999) Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154:721–727
Article CAS PubMed PubMed Central Google Scholar
Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F et al (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Can Res 62:809–818
Steidl C, Simon R, Bürger H, Brinkschmidt C, Hertle L, Böcker W et al (2002) Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 198:115–120
Weyerer V, Stoehr R, Bertz S, Lange F, Geppert CI, Wach S et al (2021) Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol 39:4011–4019
Article CAS PubMed PubMed Central Google Scholar
Gofrit ON, Pode D, Pizov G, Duvdevani M, Landau EH, Hidas G et al (2018) ‘Very-low-risk’ bladder tumours - a new entity? BJU Int 121:627–631
Lee A, Lee HJ, Huang HH, Ho H, Chen K (2019) Low-risk non-muscle-invasive bladder cancer: further prognostic stratification into the “very-low-risk” group based on tumor size. Int J Urol 26:481–486
Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967–3972
留言 (0)